Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Author information

Affiliations

  • 1. From the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (A.G.E., B.T.H., T.B., C.R.); the European Medicines Agency, London (E.B.); Läkemedelsverket, Uppsala, Sweden (K.D.); and the Dutch Medicines Evaluation Board, Utrecht, the Netherlands (P.A.G.).
      Authors
    • Egan AG 1
    (1 author)

ORCIDs linked to this article

The New England Journal of Medicine, 01 Feb 2014, 370(9):794-797
https://doi.org/10.1056/nejmp1314078 PMID: 24571751 

This article has been corrected. See N Engl J Med. 2014 Jun 5;370(23):2253.

Abstract 

No abstract provided.

Full text links 

Read article at publisher's site: https://doi.org/10.1056/nejmp1314078

References 

Articles referenced by this article (4)

Citations & impact 

Impact metrics

273
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/2152151
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/2152151

Article citations

Go to all (273) article citations

Other citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.